These results indicate that the combination of FLT3 and AXL inhibition prevented leukemia cell recovery for several days after stopping treatment, highlighting how this combination can have lasting effects on leukemia cells and has the potential to improve treatment outcomes. Here, FLT3 is linked to leukemia.